drug · cell
deramiocel
pre_registrationupdated 7mo agoby $CAPR CAPRICOR THERAPEUTICS, INC.🔗 ChEMBL
community read0 votes
Cell drug with a maximum clinical stage of Phase 2, with 1 investigational indication.
indications
indications
Duchenne Muscular Dystrophy
all catalysts(0)
nothing on the calendar yet
Trials studying deramiocel
News(10)
- Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trialCapricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In aendpoints · 5h ago
- STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time comingThe FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.stat · 7h ago
- Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nearsAwaiting a decision on Nov. 22 for its embattled Duchenne muscular dystrophy cell therapy deramiocel, Capricor has reduced its workforce by 10% and slowed programs not directly related to deramioce…biospace · 9d ago
- Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapyLess than two weeks away from a highly anticipated FDA ruling on its cell therapy for Duchenne muscular dystrophy, Capricor Therapeutics has reported increased investment in its San Diego plant to…biospace · 9d ago
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 9d ago
- Capricor, NextCure shed light on recent layoffs as they gear up for approval decision, mergerCapricor and NextCure have shed light on recent rounds of layoffs, as the biotechs brace for a hoped-for drug approval and merger, respectively.fiercebiotech · 10d ago
- FDA's rare disease framework faces its first real test in Capricor’s DMD drugLast month, the FDA committed to designing a "fit-for-purpose" framework for regulating rare disease therapies based on patient need and realistically attainable evidence. With the upcoming decisio…biospace · 10d ago
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked NovemberAlso lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.biospace · 14d ago
- FDA's latest rare disease framework seeks to prioritize consistency in flexibilityFollowing several recent initiatives, the FDA's newest rare disease framework sets out to standardize the agency's approach to scientific evidence and bring rare disease therapies to patients faster.biospace · 1mo ago
- US senators grill FDA nominee Overton on ability to ‘stand up’ to TrumpIn Thursday’s Senate committee meeting, FDA commissioner nominee Heidi Overton was repeatedly questioned about her ability to retain the FDA’s independence under President Donald Trump, as well as…biospace · 1mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that